Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
|Articles|March 1, 2019

Sartorius Stedim Biotech

The Sartorius Group is a leading international partner of the biopharmaceutical industry and the research sector.

Many diseases, such as cancer, dementia, or inflammatory diseases, are still incurable. Hundreds of millions of people lack access to affordable and safe medicines. Our biopharma customers are working hard to develop new drugs to improve people’s lives. For that they need strong partners to be successful. The Sartorius Group is a leading international partner of the biopharmaceutical industry and the research sector. We are helping biotech scientists and engineers across the entire globe to develop and manufacture medications from the first idea to production so more people will have access to better medicine. 

Sartorius Stedim Biotech
INNOPHEX Booth #4249


Related to this article

The BioPharm Brief: FDA’s Fast-Track Pilot Reportedly Stalls, a Long-Acting Bispecific for Atopic Dermatitis, and a Twice-Yearly Obesity Approach
FDA has reportedly shelved its Commissioner’s National Priority Voucher pilot and paused publishing complete response letters, Zai Lab’s IL-13/IL-31Rα bispecific ZL-1503 shows a 40- to 50-day half-life that points to dosing every 12 weeks, and Wave Life Sciences reports 1-year INLIGHT data for its INHBE-silencing siRNA WVE-007 in obesity.